Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes

Sponsor
Novo Nordisk A/S
Study ID
NCT01509742
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
30 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
    Single dose of 7.5 mcg/kg, injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement
  • placebo — DRUG
    Single dose injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement

Study Details

This trial is conducted in Europe. The aim of this trial is to examine the effect of NNC 90-1170 on the hypoglycaemic counterregulation in subjects with type 2 diabetes.

Key Dates

Start date
Apr 30, 2001
Status verified
Jan 2024
Primary completion
Nov 30, 2001
Completion
Nov 30, 2001

Study Design

Enrollment
19 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: NNC 90-1170
  • Placebo Comparator: Placebo

Primary Outcome Measure

Area under the Curve (AUC) glucagon

Related Studies